Monson Jonathan 4

What Happened

• Jonathan Monson, Executive Vice President and Chief Financial Officer of Boston Scientific (BSX), had restricted stock units (RSUs) vest/convert into 3,814 shares across Feb 13–16, 2026. The RSUs converted at $0 exercise price (code M).
• To satisfy tax withholding (code F), 1,698 shares were surrendered/withheld at a reported price of $74.73 per share, generating proceeds of $126,891. Net shares delivered to Monson after withholding: 2,116 (worth about $158,129 at $74.73/share).
• This was an RSU settlement with share withholding for taxes (routine compensation-related activity), not an open-market purchase or voluntary sale.

Key Details

• Transaction dates and prices:
  • Feb 13, 2026: 1,766 RSUs converted; 788 shares withheld for taxes at $74.73 ($58,887).
  • Feb 14, 2026: 1,058 RSUs converted; 470 shares withheld at $74.73 ($35,123).
  • Feb 16, 2026: 990 RSUs converted; 440 shares withheld at $74.73 ($32,881).
• Total converted: 3,814 RSUs; total withheld: 1,698 shares; total withholding value: $126,891; net shares retained: 2,116.
• Footnotes: F1–F4 indicate these are restricted stock units (each unit = 1 share) that vest/are issued in four equal annual installments beginning on the dates listed for the respective grants.
• Shares owned after the transactions are not shown in the data provided here.
• Filing timeliness: Form filed 2026-02-18 for transactions beginning 2026-02-13. This appears later than the usual two-business-day Form 4 deadline (flagged as late), which reduces immediacy of disclosure.

Context

• These entries reflect conversion/settlement of RSUs and withholding of shares to cover tax obligations (a common, routine post-vesting action), not a market purchase or directional bet by the insider.
• Derivative code M denotes conversion/exercise of the award; code F denotes shares withheld/surrendered to cover tax withholding (functionally similar to a cashless sale of a portion of the vested award).